CD8A and cancer: Both CD4 T cell subsets were needed for the therapeutic effect of cGAMP.[14] Moreover, STING activation in DCs enhanced the presentation of tumor‐associated antigens to CD8+ T cells on major histocompatibility complex I (MHCI),[15] hence amplifying CD8+ T cell expansion and trafficking to the tumor site.[16] The killing of tumor cells through the CD8+ T cells increased the release of additional tumor antigens, further activating DCs, and promoting the initiation of the cancer‐immunity cycle.[17]